Learn about the Stock Drop Intelligence Agent

Every week, markets move. Understanding why a stock dropped matters just as much as knowing that it dropped. This agent automates that research pipeline with a strict focus on precision and cost-efficiency.

Deterministic Filtering

Rather than sending broad queries to an AI, the agent starts with the numbers. It pulls 5-day closing prices for every tracked ticker from standard financial data providers and ranks them by percentage change. Only the worst-performing stocks with confirmed negative returns advance to the next stage, which eliminates guesswork and unnecessary processing costs.

Headline Triage

For each declining stock, the agent fetches raw RSS headlines from public news feeds. It only pulls the titles rather than full article content. These lightweight strings are sent to an AI model with a strict prompt to identify the top headlines most likely to explain a short-term price drop. Because headlines use very little text, this step costs a fraction of what full-article analysis would. Generic price trackers, standard institutional filings, and positive news are filtered out before a single full article is ever downloaded.

Targeted Deep Analysis

Only the selected headlines have their full article text extracted and scraped. That specific content is then passed to the AI to produce a concise summary for each article, along with a synthesized conclusion explaining the broader picture behind the stock's decline.

The Final Report

The result is a fully rendered HTML report that requires zero manual research. Each falling stock gets its own card showing the drop, the relevant headlines, individual article summaries, and an overall analyst-style conclusion. The entire process is generated automatically at a minimal token cost every time it runs.

Stocks in this report

Apple Inc.
AAPL
Performance (5d) ↘ -8.52%
AAPL Stock Slides Nearly 10% — Apple’s Earnings Divide Wall Street, But Retail Sees A Buying Opportunity - TradingView Apple's stock fell nearly 10% following weaker-than-expected fourth-quarter reve … Read more ▾ Collapse ▴
Apple's stock fell nearly 10% following weaker-than-expected fourth-quarter revenue guidance, with Wall Street analysts divided on near-term versus long-term prospects. Key headwinds cited include supply constraints, rising memory costs, and margin pressure, though some analysts like TD Cowen and Wells Fargo remain constructive with raised price targets. Retail traders on Stocktwits turned bullish despite the selloff, viewing the decline as a buying opportunity rather than a fundamental deterioration.

Apple's recent 10% stock decline stems primarily from weaker-than-expected Q4 revenue guidance that exposed near-term operational challenges including supply chain constraints and rising memory costs pressuring margins. While Wall Street remains divided, with some analysts raising price targets based on long-term growth catalysts (2nm chips, product price increases, Services growth), the immediate outlook is clouded by component availability issues and inflation pressures that could impact near-term profitability. The disconnect between bullish retail sentiment and cautious analyst positioning suggests the market is pricing in near-term headwinds while longer-term investors see value at current levels.

Eli Lilly and Company
LLY
Performance (5d) ↘ -7.80%

No relevant articles found.

No summary available.

AbbVie Inc.
ABBV
Performance (5d) ↘ -7.41%
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat - Benzinga AbbVie beat Q2 earnings expectations with adjusted diluted EPS of $3.65 (vs. $3. … Read more ▾ Collapse ▴
AbbVie beat Q2 earnings expectations with adjusted diluted EPS of $3.65 (vs. $3.60 consensus) and revenue of $16.99 billion (vs. $16.765 billion estimate), representing strong year-over-year growth of 22.9% and 10.2% respectively. However, the company trimmed its full-year earnings guidance to $13.87-$14.07 from $13.91-$14.11, primarily due to the pending Apogee Therapeutics acquisition expected to close in Q3, which will reduce 2026 earnings by 14 cents per share. The guidance reduction overshadowed the earnings beat, causing ABBV shares to decline 2.01% to $252.24.

AbbVie's stock decline was driven by a disappointing full-year earnings guidance reduction despite strong Q2 operational results. The primary culprit is the company's planned acquisition of Apogee Therapeutics, which will create a significant 14-cent headwind to 2026 earnings, outweighing a 10-cent operational improvement. Additionally, the company has absorbed substantial in-process R&D charges and milestone payments totaling 58 cents per share through the first half of the year. Investors appear to have reacted negatively to the forward-looking earnings pressure from the acquisition and accumulated R&D expenses, viewing these as material headwinds that offset the company's solid near-term earnings performance.

Philip Morris International Inc
PM
Performance (5d) ↘ -5.81%
Philip Morris International (PM) Could Be 3% Below Fair Value After Brazil Lawsuit Progress - simplywall.st Philip Morris International (PM) experienced a recent 1-day decline of 1.79% and … Read more ▾ Collapse ▴
Philip Morris International (PM) experienced a recent 1-day decline of 1.79% and 7-day fall of 6.37%, though the stock remains up 16.91% year-to-date. A landmark Brazilian lawsuit against cigarette makers has reached a key procedural milestone with all legal submissions complete, awaiting a liability ruling. Despite legal risks and heavy investment in smoke-free alternatives like ZYN, PM trades at a 3% discount to fair value estimates, suggesting potential undervaluation if the company's smoke-free growth strategy continues as expected.

Philip Morris International's recent stock decline appears to be driven primarily by concerns over a significant Brazilian lawsuit that has progressed to the liability ruling stage, creating near-term legal uncertainty for the company. While the stock's longer-term fundamentals remain supported by strong growth in smoke-free products (IQOS, ZYN, VEEV) and secular shifts toward reduced-risk alternatives, investors are pricing in caution around potential legal liabilities and regulatory risks. The current valuation at a 3% discount to fair value suggests the market is appropriately reflecting these legal headwinds, though the stock's year-to-date gains of nearly 17% indicate confidence in the company's smoke-free transition strategy offsetting some of the lawsuit concerns.

Linde plc
LIN
Performance (5d) ↘ -5.19%
Linde: My 'Not Cheap' Thesis Has Been True Since 2023 (NASDAQ:LIN) - Seeking Alpha An analyst maintains a 'Hold' rating on Linde despite strong fundamentals, citin … Read more ▾ Collapse ▴
An analyst maintains a 'Hold' rating on Linde despite strong fundamentals, citing excessive valuation at 27x-30x P/E that requires unrealistic growth to justify current levels. The analyst sets a fair value of $340/share and notes that capital allocation through buybacks at high multiples raises concerns about shareholder value creation.
Linde plc (NASDAQ:LIN) Shares Fall 6% After Capex Boost Surpasses EPS Gain - TechStock² Linde shares fell 5.9% after the company raised 2026 capital expenditure guidanc … Read more ▾ Collapse ▴
Linde shares fell 5.9% after the company raised 2026 capital expenditure guidance by 9.5% while only increasing adjusted EPS guidance by 0.3%, signaling a significant shift toward capital intensity. The earnings beat expectations on revenue and EPS, but the disproportionate capex increase relative to earnings growth disappointed investors.
Linde PLC Stock (LIN) Moved Down by 5.66% on Jul 31: Drivers Behind the Movement - TradingKey Linde's 5.66% decline reflects investor concerns about cooling demand in Europea … Read more ▾ Collapse ▴
Linde's 5.66% decline reflects investor concerns about cooling demand in European and Chinese markets, margin pressures from clean energy transition projects, and analyst downgrades citing potential prolonged weakness in the semiconductor segment. The stock is experiencing a valuation reset as long-term growth assumptions are adjusted downward amid broader sector rotation away from materials.

Linde's recent stock decline stems from a confluence of valuation and operational concerns. While the company delivered solid Q2 earnings, the significant increase in capital expenditure guidance (9.5%) relative to minimal earnings growth (0.3%) signaled deteriorating capital efficiency and raised questions about near-term cash flow generation. Additionally, management's cautious commentary on cooling industrial demand in key markets like Europe and China, combined with margin pressures from clean energy transition projects and weakness in the semiconductor segment, has prompted analyst downgrades and a market reassessment of the company's growth trajectory. The stock's premium valuation, which was previously justified by steady growth assumptions, is now facing scrutiny as investors recalibrate expectations in a more uncertain macroeconomic environment.